# A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study

> **NCT03236506** · PHASE2 · COMPLETED · sponsor: **University of Dundee** · enrollment: 129 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
- **BEHAVIORAL:** Psychological intervention
- **DRUG:** Sofosbuvir 400 MG

## Key facts

- **NCT ID:** NCT03236506
- **Lead sponsor:** University of Dundee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-10-28
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236506, "A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03236506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*